BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Lithera Wraps Up $35.6 Million Series C Funding Round


2/11/2014 7:06:50 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Lithera Announces Final Closing of $35.6 Million Series C Financing

SAN DIEGO, Feb. 11, 2014 (GLOBE NEWSWIRE) -- Lithera, Inc. ("Lithera" or "the Company"), a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, today announced that it has completed the final closing of its Series C preferred stock equity financing, securing an additional $8.0 million in equity capital and bringing the total capital raised in this round to $35.6 million. This tranche included existing investors Alta Partners and Domain Associates, new investor AKS Capital, LLC, as well as additional undisclosed investors.

Lithera expects to use the proceeds for general corporate and working capital purposes, primarily to support clinical, regulatory, and manufacturing efforts to advance the Company's lead product candidate, LIPO-202 (Salmeterol Xinafoate for Injection), a novel, physician-administered, injectable pharmaceutical product designed to produce localized non-ablative reduction of subcutaneous abdominal fat.

"Securing this final tranche of the Series C financing from new and existing investors demonstrates continued confidence in LIPO-202," said George Mahaffey, President and CEO of Lithera. "LIPO-202 has the potential to be the first and only injectable drug treatment for the targeted, non-ablative reduction of subcutaneous abdominal fat. This funding will help build on the robust clinical profile established to date for LIPO-202."

About Lithera:

Lithera is a clinical stage company developing pharmaceutical products addressing both lifestyle and medical indications in aesthetic medicine and ophthalmology. Using FDA-registered drugs approved for use in other indications, Lithera's products target and stimulate natural fat tissue metabolism to achieve non-ablative, non-surgical fat tissue reduction in specific locations. Our lead product candidate, LIPO-202 (Salmeterol Xinafoate for Injection), is a novel injectable pharmaceutical product designed to produce local, selective, non-ablative fat tissue reduction (pharmaceutical lipoplasty). LIPO-202 is currently under development for the reduction of central abdominal bulging in non-obese patients (BMI less than 30 kg/m2). LIPO-102 (Salmeterol Xinafoate and Fluticasone Propionate for Injection) is currently under development for the treatment of symptomatic exophthalmos (protrusion of the eye from the orbit) associated with thyroid-related eye disease (also known as Graves' Orbitopathy). Founded in 2007, the Company has assembled an exceptional team of senior executives, employees and advisors and has been financed by top-tier venture capital firms. For more information on Lithera, Inc., please visit www.lithera.com.

Lithera, LIPO-102, LIPO-202 and the Lithera logo are trademarks or registered trademarks of Lithera, Inc. Other names and brands may be claimed as the property of others.

Contact:

Lithera, Inc.:
Susan Knudson
Vice President, Finance & Administration
858-750-1008
sknudson@lithera.com
Investor Relations:
Fara Berkowitz
Argot Partners
212-600-1902
fara@argotpartners.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

Lithera
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES